Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7-10 Prostate Cancer Treated With Permanent Prostate Brachytherapy

Nelson N. Stone, Louis Potters, Brian J. Davis, Jay P. Ciezki, Michael J. Zelefsky, Mack Roach, Katsuto Shinohara, Paul A. Fearn, Michael W. Kattan, Richard G. Stock

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Purpose: To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED). Methods and Materials: Six centers provided data on 5,889 permanent prostate brachytherapy patients, of whom 1,078 had Gleason score 7 (n = 845) or Gleason score 8-10 (n = 233) prostate cancer and postimplant dosimetry results available. The median prostate-specific antigen level was 7.5 ng/mL (range, 0.4-300). The median follow-up for censored patients was 46 months (range, 5-130). Short-term hormonal therapy (median duration, 3.9 months) was used in 666 patients (61.8%) and supplemental external beam radiotherapy (EBRT) in 620 (57.5%). The patients were stratified into three BED groups: <200 Gy (n = 645), 200-220 Gy (n = 199), and >220 Gy (n = 234). Biochemical freedom from failure (bFFF) was determined using the Phoenix definition. Results: The 5-year bFFF rate was 80%. The bFFF rate stratified by the three BED groups was 76.4%, 83.5%, and 88.3% (p < 0.001), respectively. Cox regression analysis revealed Gleason score, prostate-specific antigen level, use of hormonal therapy, EBRT, and BED were associated with bFFF (p < 0.001). Freedom from metastasis improved from 92% to 99% with the greatest doses. The overall survival rate at 5 years for the three BED groups for Gleason score 8-10 cancer was 86.6%, 89.4%, and 94.6%, respectively (p = 0.048). Conclusion: These data suggest that permanent prostate brachytherapy combined with EBRT and hormonal therapy yields excellent bFFF and survival results in Gleason score 7-10 patients when the delivered BEDs are >220 Gy. These doses can be achieved by a combination of 45-Gy EBRT with a minimal dose received by 90% of the target volume of 120 Gy of 103Pd or 130 Gy of 125I.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume73
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Neoplasm Grading
Brachytherapy
Prostate
Prostatic Neoplasms
cancer
dosage
Survival
radiation therapy
Radiotherapy
Phoenix (AZ)
antigens
Prostate-Specific Antigen
dosimeters
therapy
Survival Rate

Keywords

  • Biologic equivalent dose
  • Brachytherapy
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7-10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. / Stone, Nelson N.; Potters, Louis; Davis, Brian J.; Ciezki, Jay P.; Zelefsky, Michael J.; Roach, Mack; Shinohara, Katsuto; Fearn, Paul A.; Kattan, Michael W.; Stock, Richard G.

In: International Journal of Radiation Oncology Biology Physics, Vol. 73, No. 2, 01.02.2009, p. 341-346.

Research output: Contribution to journalArticle

Stone, Nelson N. ; Potters, Louis ; Davis, Brian J. ; Ciezki, Jay P. ; Zelefsky, Michael J. ; Roach, Mack ; Shinohara, Katsuto ; Fearn, Paul A. ; Kattan, Michael W. ; Stock, Richard G. / Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7-10 Prostate Cancer Treated With Permanent Prostate Brachytherapy. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 73, No. 2. pp. 341-346.
@article{322ced14e1814aac9a8bb77fe603eb3c,
title = "Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7-10 Prostate Cancer Treated With Permanent Prostate Brachytherapy",
abstract = "Purpose: To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED). Methods and Materials: Six centers provided data on 5,889 permanent prostate brachytherapy patients, of whom 1,078 had Gleason score 7 (n = 845) or Gleason score 8-10 (n = 233) prostate cancer and postimplant dosimetry results available. The median prostate-specific antigen level was 7.5 ng/mL (range, 0.4-300). The median follow-up for censored patients was 46 months (range, 5-130). Short-term hormonal therapy (median duration, 3.9 months) was used in 666 patients (61.8{\%}) and supplemental external beam radiotherapy (EBRT) in 620 (57.5{\%}). The patients were stratified into three BED groups: <200 Gy (n = 645), 200-220 Gy (n = 199), and >220 Gy (n = 234). Biochemical freedom from failure (bFFF) was determined using the Phoenix definition. Results: The 5-year bFFF rate was 80{\%}. The bFFF rate stratified by the three BED groups was 76.4{\%}, 83.5{\%}, and 88.3{\%} (p < 0.001), respectively. Cox regression analysis revealed Gleason score, prostate-specific antigen level, use of hormonal therapy, EBRT, and BED were associated with bFFF (p < 0.001). Freedom from metastasis improved from 92{\%} to 99{\%} with the greatest doses. The overall survival rate at 5 years for the three BED groups for Gleason score 8-10 cancer was 86.6{\%}, 89.4{\%}, and 94.6{\%}, respectively (p = 0.048). Conclusion: These data suggest that permanent prostate brachytherapy combined with EBRT and hormonal therapy yields excellent bFFF and survival results in Gleason score 7-10 patients when the delivered BEDs are >220 Gy. These doses can be achieved by a combination of 45-Gy EBRT with a minimal dose received by 90{\%} of the target volume of 120 Gy of 103Pd or 130 Gy of 125I.",
keywords = "Biologic equivalent dose, Brachytherapy, Prostate cancer",
author = "Stone, {Nelson N.} and Louis Potters and Davis, {Brian J.} and Ciezki, {Jay P.} and Zelefsky, {Michael J.} and Mack Roach and Katsuto Shinohara and Fearn, {Paul A.} and Kattan, {Michael W.} and Stock, {Richard G.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.ijrobp.2008.04.038",
language = "English (US)",
volume = "73",
pages = "341--346",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7-10 Prostate Cancer Treated With Permanent Prostate Brachytherapy

AU - Stone, Nelson N.

AU - Potters, Louis

AU - Davis, Brian J.

AU - Ciezki, Jay P.

AU - Zelefsky, Michael J.

AU - Roach, Mack

AU - Shinohara, Katsuto

AU - Fearn, Paul A.

AU - Kattan, Michael W.

AU - Stock, Richard G.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Purpose: To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED). Methods and Materials: Six centers provided data on 5,889 permanent prostate brachytherapy patients, of whom 1,078 had Gleason score 7 (n = 845) or Gleason score 8-10 (n = 233) prostate cancer and postimplant dosimetry results available. The median prostate-specific antigen level was 7.5 ng/mL (range, 0.4-300). The median follow-up for censored patients was 46 months (range, 5-130). Short-term hormonal therapy (median duration, 3.9 months) was used in 666 patients (61.8%) and supplemental external beam radiotherapy (EBRT) in 620 (57.5%). The patients were stratified into three BED groups: <200 Gy (n = 645), 200-220 Gy (n = 199), and >220 Gy (n = 234). Biochemical freedom from failure (bFFF) was determined using the Phoenix definition. Results: The 5-year bFFF rate was 80%. The bFFF rate stratified by the three BED groups was 76.4%, 83.5%, and 88.3% (p < 0.001), respectively. Cox regression analysis revealed Gleason score, prostate-specific antigen level, use of hormonal therapy, EBRT, and BED were associated with bFFF (p < 0.001). Freedom from metastasis improved from 92% to 99% with the greatest doses. The overall survival rate at 5 years for the three BED groups for Gleason score 8-10 cancer was 86.6%, 89.4%, and 94.6%, respectively (p = 0.048). Conclusion: These data suggest that permanent prostate brachytherapy combined with EBRT and hormonal therapy yields excellent bFFF and survival results in Gleason score 7-10 patients when the delivered BEDs are >220 Gy. These doses can be achieved by a combination of 45-Gy EBRT with a minimal dose received by 90% of the target volume of 120 Gy of 103Pd or 130 Gy of 125I.

AB - Purpose: To investigate the biochemical control rates and survival for Gleason score 7-10 prostate cancer patients undergoing permanent prostate brachytherapy as a function of the biologic effective dose (BED). Methods and Materials: Six centers provided data on 5,889 permanent prostate brachytherapy patients, of whom 1,078 had Gleason score 7 (n = 845) or Gleason score 8-10 (n = 233) prostate cancer and postimplant dosimetry results available. The median prostate-specific antigen level was 7.5 ng/mL (range, 0.4-300). The median follow-up for censored patients was 46 months (range, 5-130). Short-term hormonal therapy (median duration, 3.9 months) was used in 666 patients (61.8%) and supplemental external beam radiotherapy (EBRT) in 620 (57.5%). The patients were stratified into three BED groups: <200 Gy (n = 645), 200-220 Gy (n = 199), and >220 Gy (n = 234). Biochemical freedom from failure (bFFF) was determined using the Phoenix definition. Results: The 5-year bFFF rate was 80%. The bFFF rate stratified by the three BED groups was 76.4%, 83.5%, and 88.3% (p < 0.001), respectively. Cox regression analysis revealed Gleason score, prostate-specific antigen level, use of hormonal therapy, EBRT, and BED were associated with bFFF (p < 0.001). Freedom from metastasis improved from 92% to 99% with the greatest doses. The overall survival rate at 5 years for the three BED groups for Gleason score 8-10 cancer was 86.6%, 89.4%, and 94.6%, respectively (p = 0.048). Conclusion: These data suggest that permanent prostate brachytherapy combined with EBRT and hormonal therapy yields excellent bFFF and survival results in Gleason score 7-10 patients when the delivered BEDs are >220 Gy. These doses can be achieved by a combination of 45-Gy EBRT with a minimal dose received by 90% of the target volume of 120 Gy of 103Pd or 130 Gy of 125I.

KW - Biologic equivalent dose

KW - Brachytherapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=58149327450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149327450&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.04.038

DO - 10.1016/j.ijrobp.2008.04.038

M3 - Article

C2 - 18597953

AN - SCOPUS:58149327450

VL - 73

SP - 341

EP - 346

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -